BofA analyst Geoff Meacham raised the firm’s price target on BioMarin to $200 from $120 and keeps a Buy rating on the shares, telling investors that based on his discussions key opinion leading physicians that he has "high conviction" in initial Roctavian adoption, particularly in the U.S. Voxzogo launch revenues have beaten every quarter and he suspects Voxzogo’s execution will begin to quell concerns over the opportunity, Meacham added. In addition, the firm is adding BioMarin to its "US 1 List," intended to represent a collection of its best investment ideas that are drawn from the universe of Buy-rated, U.S.-listed stocks, while removing Pfizer (PFE) and PayPal (PYPL) from the "US 1" list.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin’s application for Voxzogo in achondroplasia validated by EMA
- BioMarin price raises ‘more aggressive’ in 2023, says Piper Sandler
- BioMarin price target raised to $120 from $100 at Jefferies
- BioMarin should rally ‘meaningfully’ after Ascendis data, says Piper Sandler
- ‘History points to a post-midterm rally:’ Oppenheimer suggests 3 stocks to ride the momentum